Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease
Renalytix (OTCQB: RNLXY) has partnered with Tempus AI (NASDAQ: TEM) to expand the availability of its FDA-approved kidneyintelX.dkd prognostic blood test. The test helps predict risk levels for kidney function decline in patients with type 2 diabetes and chronic kidney disease stages 1-3b, affecting nearly 15 million individuals in the US.
The collaboration leverages Tempus's extensive clinical network and AI-enabled platform to integrate kidneyintelX.dkd testing into existing clinical workflows. The test will be processed in Renalytix's laboratory, with results reported electronically to clinicians and patient portals, enabling timely interventions to improve diabetes and kidney care outcomes.
Renalytix (OTCQB: RNLXY) ha stretto una partnership con Tempus AI (NASDAQ: TEM) per allargare la disponibilità del suo test sanguigno prognostico kidneyintelX.dkd approvato dalla FDA. Il test aiuta a prevedere i livelli di rischio di declino della funzione renale in pazienti con diabete di tipo 2 e malattia renale cronica negli stadi 1-3b, interessando quasi 15 milioni di individui negli Stati Uniti. La collaborazione sfrutta la vasta rete clinica di Tempus e la piattaforma abilitata dall'AI per integrare i test kidneyintelX.dkd nei flussi clinici esistenti. Il test verrà processato nel laboratorio di Renalytix, con i risultati segnalati elettronicamente a medici e portali dei pazienti, consentendo interventi tempestivi per migliorare la cura del diabete e della salute renale.
Renalytix (OTCQB: RNLXY) se ha asociado con Tempus AI (NASDAQ: TEM) para ampliar la disponibilidad de su prueba de sangre pronóstica aprobada por la FDA, kidneyintelX.dkd. La prueba ayuda a predecir los niveles de riesgo de deterioro de la función renal en pacientes con diabetes tipo 2 y enfermedad renal crónica en los estadios 1-3b, afectando a casi 15 millones de personas en EE. UU. La colaboración aprovecha la extensa red clínica de Tempus y su plataforma habilitada por IA para integrar las pruebas de kidneyintelX.dkd en los flujos clínicos existentes. La prueba se procesará en el laboratorio de Renalytix, con los resultados reportados de forma electrónica a médicos y portales de pacientes, lo que permite intervenciones a tiempo para mejorar los cuidados del diabetes y la función renal.
Renalytix (OTCQB: RNLXY)은 FDA 승인 혈액검사 kidneyintelX.dkd의 이용 가능성을 확장하기 위해 Tempus AI (NASDAQ: TEM)과 파트너십을 체결했습니다. 이 검사는 제2형 당뇨병 및 1-3b단계의 만성 신장 질환 환자의 신장 기능 저하 위험 수준을 예측하는 데 도움이 되며, 미국에서 거의 1,500만 명에게 영향을 미칩니다. 협력은 Tempus의 광범위한 임상 네트워크와 AI 기반 플랫폼을 활용하여 kidneyintelX.dkd 검사를 기존 임상 워크플로우에 통합합니다. 이 검사는 Renalytix의 연구소에서 처리되며, 의사와 환자 포털에 전자적으로 결과가 보고되어 당뇨병 및 신장 관리 결과를 개선하기 위한 시기의 중재를 가능하게 합니다.
Renalytix (OTCQB : RNLXY) s'est associé à Tempus AI (NASDAQ : TEM) pour étendre la disponibilité de son test sanguin pronostique approuvé par la FDA, kidneyintelX.dkd. Le test aide à prédire les niveaux de risque de déclin de la fonction rénale chez les patients atteints de diabète de type 2 et de maladie rénale chronique stades 1-3b, touchant près de 15 millions de personnes aux États‑Unis. La collaboration exploite le vaste réseau clinique de Tempus et sa plateforme alimentée par l'IA pour intégrer les tests kidneyintelX.dkd dans les flux de travail cliniques existants. Le test sera traité dans le laboratoire de Renalytix, les résultats étant signalés électroniquement aux cliniciens et aux portails des patients, permettant des interventions en temps utile pour améliorer les soins du diabète et de la fonction rénale.
Renalytix (OTCQB: RNLXY) hat eine Partnerschaft mit Tempus AI (NASDAQ: TEM) geschlossen, um die Verfügbarkeit ihres FDA-zugelassenen prognostischen Bluttests kidneyintelX.dkd zu erweitern. Der Test hilft, Risikoniveaus für den Rückgang der Nierenfunktion bei Patienten mit Typ-2-Diabetes und chronischer Nierenerkrankung Stadien 1-3b vorherzusagen und betrifft fast 15 Millionen Menschen in den USA. Die Zusammenarbeit nutzt Tempus' umfangreiches klinisches Netzwerk und die AI-basierte Plattform, um kidneyintelX.dkd-Tests in bestehende klinische Arbeitsabläufe zu integrieren. Der Test wird im Labor von Renalytix verarbeitet, und Ergebnisse werden elektronisch an Kliniker und Patientenportale gemeldet, was rechtzeitige Interventionen zur Verbesserung der Diabetes- und Nierengesundheit ermöglicht.
Renalytix (OTCQB: RNLXY) أبرمت شراكة مع Tempus AI (NASDAQ: TEM) لتوسيع توافر اختبار الدم التنبؤي المعتمد من FDA kidneyintelX.dkd. يساعد الاختبار في توقع مستويات مخاطر تدهور وظيفة الكلى لدى المرضى المصابين بمرض السكري من النوع 2 ومرض الكلى المزمن في المراحل 1-3b، وهو يؤثر على ما يقرب من 15 مليون شخص في الولايات المتحدة. تستفيد الشراكة من شبكة Tempus السريرية الواسعة والمنصة المعتمدة على الذكاء الاصطناعي لدمج فحص kidneyintelX.dkd في سير العمل السريري القائم. سيُعالج الاختبار في مختبر Renalytix، وسيتم الإبلاغ عن النتائج إلكترونيًا للأطباء وبوابات المرضى، مما يتيح تدخلاً في الوقت المناسب لتحسين رعاية مرضى السكري والكلى.
Renalytix (OTCQB: RNLXY) 已与 Tempus AI (NASDAQ: TEM) 合作，扩大其经 FDA 批准的预测性血液测试 kidneyintelX.dkd 的可用性。该测试有助于预测2型糖尿病与慢性肾病1-3b阶段患者的肾功能下降风险水平，影响美国近 1500万名 患者。合作利用 Tempus 的广泛临床网络和 AI 驱动的平台，将 kidneyintelX.dkd 测试整合到现有临床工作流程中。测试将在 Renalytix 实验室处理，结果将电子方式报告给临床医生和患者门户，从而实现及时干预，改善糖尿病及肾病护理效果。
- Partnership expands access to FDA-approved kidneyintelX.dkd test across Tempus's broad US healthcare network
- Test addresses a large market of 15 million US patients with type 2 diabetes and chronic kidney disease
- Integration with existing clinical workflows should accelerate adoption
- Medicare reimbursement already secured for the test
- No financial terms or revenue projections disclosed
- Implementation timeline and specific adoption targets not provided
Insights
Tempus-Renalytix partnership expands distribution of kidney disease AI test, potentially boosting adoption and revenue in a 15M patient market.
This collaboration between Tempus and Renalytix represents a strategic expansion for both companies' AI-driven healthcare platforms. For Tempus, this marks their first entry into the chronic kidney disease diagnostic space, while Renalytix gains access to Tempus' extensive clinical network to drive adoption of their FDA-approved, Medicare-reimbursed kidneyintelX.dkd test.
The market potential is substantial - the agreement targets the ~15 million Americans with type 2 diabetes and chronic kidney disease. Importantly, kidneyintelX.dkd is positioned as a risk stratification tool for progressive kidney function decline, enabling earlier intervention in this high-cost chronic disease area.
Beyond immediate test adoption, this partnership offers long-term strategic value through multi-modal data accumulation in the cardiovascular-renal-metabolic disease space. The collaboration will integrate the test into existing clinical workflows, potentially reducing adoption friction while maintaining Renalytix's control over laboratory processing and results reporting.
For Tempus investors, this expands their diagnostic portfolio into a new disease category with significant market potential and aligns with their strategy of building a comprehensive multi-modal data library for AI applications. For Renalytix, partnering with Tempus' established network could accelerate commercial traction for a test that addresses both clinical outcomes and quality metrics in diabetes and kidney care management.
Definitive agreement to accelerate adoption of Renalytix's FDA-approved, Medicare reimbursed kidneyintelX.dkd test to slow kidney disease progression and improve patient outcomes
Renalytix's kidneyintelX.dkd will be the first test offered in Tempus' portfolio in the chronic kidney disease category, indicated for use as an aid in predicting level of risk (high, moderate, low) for progressive decline in kidney function in type 2 diabetes patients with diagnosed chronic kidney disease stages 1-3b.
"The unique Tempus platform, with its broad clinical reach, will allow us to significantly expand patient and clinician access to advance kidneyintelX.dkd precision medicine testing in one of the largest and costliest chronic disease conditions today," said James McCullough, CEO Renalytix. "Further, we expect our partnership to be instrumental in driving therapeutic and diagnostic innovation through multi-modal data accumulation and analysis in patients in the cardiovascular, renal and metabolic space."
"We share Renalytix's mission of developing AI-enabled diagnostics designed to support clinicians in surfacing new insights that can inform patient care. This collaboration expands our reach into the diabetes and chronic kidney disease space, and we look forward to bringing our technology to these patients," said Tempus Chief Operating Officer, Ryan Fukushima.
Under the agreement, Tempus and Renalytix will collaborate with US health systems to make testing more available for providers to order within existing clinical workflows.
The kidneyintelX.dkd tests will be processed in a Renalytix laboratory with customized patient results reported electronically to the ordering clinician and patient portal, where applicable. The test's insights allow for timely changes in patient management, which can help providers mitigate progressive decline in kidney function and improve key quality metrics in diabetes and kidney care.
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
About Chronic Kidney Disease: a worldwide public health crisis
Chronic Kidney Disease is a worldwide public health crisis impacting 850 million individuals worldwide. According to the National Kidney Foundation, it is estimated to impact more than 35 million adults in
About Renalytix
Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for kidneyintelX.dkd which is now offered commercially in
To learn more about Renalytix, visit renalytix.com, and for information about the kidneyintelX.dkd test, visit kidneyintelx.com.
For further information, please contact:
Renalytix plc
Elise Wilfinger
Chief Strategy & Marketing Officer
ewilfinger@renalytix.com
www.renalytix.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/renalytix-announces-collaboration-with-tempus-to-advance-intelligent-risk-assessment-in-diabetic-kidney-disease-302555869.html
SOURCE Renalytix plc
FAQ
What is the purpose of the Renalytix and Tempus AI collaboration announced in September 2025?
How many patients could potentially benefit from the kidneyintelX.dkd test?
What stages of chronic kidney disease is the kidneyintelX.dkd test approved for?
How will the Tempus (NASDAQ: TEM) and Renalytix partnership improve patient care?
Is the kidneyintelX.dkd test covered by Medicare?
